{"id":801253,"date":"2026-04-09T14:19:02","date_gmt":"2026-04-09T14:19:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=801253"},"modified":"2026-04-09T14:19:02","modified_gmt":"2026-04-09T14:19:02","slug":"bladder-cancer-clinical-trial-pipeline-appears-robust-with-80-key-pharma-companies-actively-working-in-the-domain-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/bladder-cancer-clinical-trial-pipeline-appears-robust-with-80-key-pharma-companies-actively-working-in-the-domain-delveinsight_801253.html","title":{"rendered":"Bladder Cancer Clinical Trial Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Domain | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/04\/1775720100.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Bladder Cancer Clinical Trial Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Domain | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/04\/1775720100.jpg\" alt=\"Bladder Cancer Clinical Trial Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Domain | DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;Bladder Cancer Pipeline Insight 2026&rdquo; <\/strong>report provides comprehensive insights about <strong>80+ companies and 100+ pipeline drugs<\/strong> in the Bladder cancer pipeline landscape. It covers the Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bladder Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>Explore our latest breakthroughs in Bladder Cancer Research @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bladder-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Bladder Cancer Pipeline Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Bladder Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong><em>On April 04, 2026- Merck Sharp &amp; Dohme LLC<\/em><\/strong> initiated a phase 2 study are to learn if people who receive V940 with BCG live longer and without the cancer growing, spreading, or coming back compared to people who receive BCG alone. The standard treatment for HR NMIBC is a procedure to remove the tumor called transurethral resection of the bladder tumor (TURBT) followed by Bacillus Calmette-Guerin (BCG). Standard treatment is something that is considered the first line of treatment for a condition. BCG is an immunotherapy, which is a treatment that helps the immune system fight cancer.<\/li>\n<li>DelveInsight&rsquo;s Bladder Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Bladder Cancer treatment.<\/li>\n<li>The leading Bladder Cancer Companies such as <strong><em>UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp &amp; Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc<\/em><\/strong>., and others.<\/li>\n<li>Promising Bladder Cancer Therapies such as <strong><em>Atezolizumab, PGV001, VAX014, BCG Vaccine, Oncofid-P-B, Oncofid-P-B,<\/em><\/strong> and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Stay informed about the cutting-edge advancements in Bladder Cancer Treatments @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bladder-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Bladder Cancer Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Bladder Cancer Overview=<\/strong><\/p>\n<p style=\"text-align: justify;\">Bladder cancer is a disease that usually begins in the cells that line the inside of the bladder. It typically affects people older than 70 and occurs more often in men. Bladder cancer is the fifth most common form of cancer overall and the fourth most common among men. Bladder cancer usually responds well to treatment when diagnosed early. However, people who have been successfully treated for bladder cancer should be monitored afterward. Bladder cancer can return even years later. About 90 percent of bladder cancers begin in the cells on the surface of the bladder&rsquo;s inner lining. This type of cancer is called urothelial carcinoma (also called transitional cell carcinoma). Most urothelial carcinoma is non-muscle invasive. That means the cancer stays within the bladder&rsquo;s inner lining. Less common types of bladder cancer include squamous cell carcinoma, adenocarcinoma, and small cell carcinoma. These types can develop in the inner lining as a result of chronic irritation and inflammation. They usually grow into the muscle of the bladder over time.<\/p>\n<p style=\"text-align: justify;\"><strong>Bladder cancer Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>UGN-102: UroGen Pharma Ltd.<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">UGN-102 (mitomycin) for intravesical solution is an investigational drug formulation of mitomycin. It is been developed by utilizing UroGen&rsquo;s proprietary RTGel&reg; technology which is a sustained release, hydrogel-based formulation, UGN-102 is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. UGN-102 is delivered to patients using a standard urinary catheter in an outpatient setting. Currently it is in Phase III stage of clinical trial for the treatment of Bladder Cancer.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>APL 1202 : Asieris Pharmaceuticals<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">APL-1202 is an orally available reversible MetAP2 Inhibitor with anti-angiogenic, anti-tumor activities and can also modulate tumor immune microenvironment. It is currently in registration clinical trials in China, either as single agent as first-line treatment for patients with intermediate-risk non-muscle invasive bladder cancer (NMIBC), or in combination with a chemotherapy as second-line treatment in patients with intermediate and high-risk chemo-refractory NMIBC. Currently, the drug is being evaluated in the Phase III stage for Bladder Cancer.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Trilaciclib: G1 Therapeutics, Inc.<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Trilaciclib, is a first-in-class therapy designed to improve outcomes for people with cancer who are treated with chemotherapy. It is a transient IV-administered CDK4\/6 inhibitor, a novel therapeutic approach which is given before chemotherapy that temporarily blocks progression through the cell cycle. Currently the drug is being evaluated in Phase II for the treatment of Bladder Cancer.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Catumaxomab: LintonPharm Co.,Ltd.<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Catumaxomab is a bispecific antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell&#8211;and CD3 on the T cell, recruits immune accessory cells through Fc&gamma;R binding at the same time. The drug kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models. The drug is in Phase I\/II stage of clinical trials for the treatment of bladder cancer.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>VAX 014: Vaxiion Therapeutics<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">VAX014 is a novel rBMC-based oncolytic immunotherapy. VAX014is a first-in-class tumor-targeted oncolytic agent based on Vaxiion&#8217;s proprietary rBMC technology. It works by specifically targeting and delivering a novel fast-acting pre-formed oncolytic protein toxin directly to tumor cells that express either &alpha;3&beta;1 or &alpha;5&beta;1 integrin(s), both commonly found to be selectively expressed in many solid tumor types. The drug is in Phase I stage of clinical trials for the treatment of bladder cancer.<\/p>\n<p style=\"text-align: justify;\"><strong>The Bladder Cancer Pipeline report provides insights into<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Bladder Cancer with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bladder Cancer Treatment.<\/li>\n<li>Bladder Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Bladder Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bladder Cancer market<strong>.<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Learn more about Bladder Cancer Drugs opportunities in our groundbreaking Bladder Cancer Research and development projects @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bladder-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Bladder Cancer Unmet Needs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Bladder Cancer Companies<\/strong><\/p>\n<p style=\"text-align: justify;\">UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp &amp; Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc., and others.<\/p>\n<p style=\"text-align: justify;\"><strong>Bladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Topical<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Bladder Cancer Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Monoclonal Antibody<\/li>\n<li>Peptides<\/li>\n<li>Polymer<\/li>\n<li>Small molecule<\/li>\n<li>Gene therapy<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Discover the latest advancements in Bladder Cancer Treatment by visiting our website @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bladder-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Bladder Cancer Market Drivers and Barriers, and Future Perspectives<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Bladder Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Bladder Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Bladder Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<li>Bladder Cancer Companies- <strong><em>UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp &amp; Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc.,<\/em><\/strong> and others<\/li>\n<li>Bladder Cancer Therapies- <strong><em>Atezolizumab, PGV001, VAX014, BCG Vaccine, Oncofid-P-B, Oncofid-P-B,<\/em><\/strong> and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>For a detailed overview of our latest research findings and future plans, read the full details of Bladder Cancer Pipeline on our website @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bladder-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Bladder Cancer Drugs and Companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Bladder Cancer Executive Summary<\/li>\n<li>Bladder Cancer: Overview<\/li>\n<li>Bladder Cancer Pipeline Therapeutics<\/li>\n<li>Bladder Cancer Pipeline Therapeutic Assessment<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>UGN-102: UroGen Pharma Ltd.<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Trilaciclib: G1 Therapeutics, Inc.<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>VAX 014: Vaxiion Therapeutics<\/li>\n<li>Inactive Products<\/li>\n<li>Bladder Cancer Key Companies<\/li>\n<li>Bladder Cancer Key Products<\/li>\n<li>Bladder Cancer &#8211; Unmet Needs<\/li>\n<li>Bladder Cancer &#8211; Market Drivers and Barriers<\/li>\n<li>Bladder Cancer &#8211; Future Perspectives and Conclusion<\/li>\n<li>Bladder Cancer Analyst Views<\/li>\n<li>Bladder Cancer Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=bladder-cancer-clinical-trial-pipeline-appears-robust-with-80-key-pharma-companies-actively-working-in-the-domain-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/bladder-cancer-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/bladder-cancer-pipeline-insight<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=bladder-cancer-clinical-trial-pipeline-appears-robust-with-80-key-pharma-companies-actively-working-in-the-domain-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s &ldquo;Bladder Cancer Pipeline Insight 2026&rdquo; report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Bladder cancer pipeline landscape. It covers the Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/bladder-cancer-clinical-trial-pipeline-appears-robust-with-80-key-pharma-companies-actively-working-in-the-domain-delveinsight_801253.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,420,413],"tags":[],"class_list":["post-801253","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/801253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=801253"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/801253\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=801253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=801253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=801253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}